Dr Anoop Enjeti
MMBS MD FRCP(UK) FACP FASCP FRCPA
Dr Anoop Enjeti is a consultant haematologist with active research interests in Microparticles/ Microvesicles (MV) and leukemia. He is a current recipient of the HCRA Fellowship Grant that partly funds his research work. Dr Enjeti completed his training in Haematology in 2006-07. He is a principal investigator for two Phase I/II trials in acute leukemia/lymphoma at his site and is active in several cooperative group trials in acute leukemia. His vision to start investigator initiated Phase I trials in MDS/AML in Newcastle with locally development molecules which show promising in-vitro activity. He believes this and the associated research into genetics, epidemiology, transfusion science and psychosocial medicine will address a number of challenging issues for patients with acute leukemia. Read more..
View Dr Enjeti's ResearchGate profile here
Dr Merran Holmes
Clinical Research Fellow, Department of Surgery, John Hunter Hospital
Dr Merran Holmes graduated from the University of Newcastle in 2012 with a Bachelor of Medicine. She completed an internship and residency with HNE Health and continued as an SRMO/unaccredited registrar in General Surgery. She has completed a Masters of Science (Surgical Science) through the University of Edinburgh, graduating last year. She is currently working as a Clinical Research Fellow through the Department of Surgery, John Hunter Hospital.
'Prehabilitation for Major Upper GI Cancer Patients' The Prehab trial is primarily looking to investigate if a structured preoperative high intensity exercise program can improve a patient's fitness for major upper gastrointestinal cancer surgery, as determined by cardiopulmonary exercise testing, radiological and biochemical markers of muscle wasting, and nutrition scoring. This randomised controlled trial is looking to recruit 100 patients requiring major surgery for upper gastrointestinal cancers at the John Hunter Hospital and Newcastle Private Hospital. The patients will be randomised to either undergo a 4 week structured exercise program set and supervised by a physiotherapist or encouraged to undertake self directed exercise for a 4 week period ahead of operation. The trial will also investigate a number of secondary outcomes including; post-operative complications, length of stay, mortality and morbidity, and look to compare the roles of different biochemical and radiological markers in evaluating patient frailty and cardiopulmonary fitness.
Dr Vanessa Wills, Conjoint Senior Lecturer
Dr Georgia Carroll
General Surgical Registrar, Department of Surgery, John Hunter Hospital
Dr Georgia Carroll undertook her medical training at the University of New England, before returning home to spend her clinical years in Newcastle, where she has worked as a Resident Medical Officer and now as a General Surgical Registrar. She is currently mid-way through her Masters of Surgical Sciences (Edinburgh) and in 2017 has commenced her PhD.
Colorectal cancer (CRC) is the commonest cancer that affects both men and women in Australia. Approximately one third of patients diagnosed with the disease die from it within five years of diagnosis. Most of these deaths occur from metastatic disease. Many of these cancers develop in patients who had no apparent metastatic disease when they were first treated with what is intended to be curative resection.
Our hypothesis is that inflammatory products (notably neutrophil extracellular traps [NETs]) are causal in metastatic disease and especially in the context of surgical sepsis, and that by inhibiting NETs, the rate of progression to metastatic disease will be reduced. We will use a mouse model for colorectal cancer to test these hypotheses. The aims of this project are to:
a)Demonstrate intrinsic interaction between circulating tumour cells and NETs formed in response to surgery and subsequent sepsis;
b) Demonstrate evidence of increased metastatic disease as a result of the inflammatory response to surgery and its complications in colorectal cancer;
c) Examine whether adjunct therapy targeting NETs and sepsis is sufficient to reduce metastasis arising from surgery.
If experimental findings are consistent with our hypotheses, it would have implications for how we treat colorectal cancer, and may translate to treatment of many other malignancies. Researcher Supervisor
Dr Simon Keely, Dr Andrea Mathe, Dr Peter Pockney, Dr Stephen Smith
Dr Asma Ashraf
Haematologist Staff Specialist, Department of Haematology, Calvary Mater Hospital
Dr Asma Ashraf completed her training in haematology in 2016 and received FRACP and FRCPA . She is currently working as haematologist staff specialist at Calvary Mater Hospital, Newcastle. She is currently also enrolled in Masters by Research at the University of Newcastle as well as enrolled in Speciality Certificate in Clinical Research at University of Melbourne. Dr Ashraf's research interests include primary bone marrow disorders in adults, transfusion medicine and rationalisation of blood product usage as well as impact of haematological cancers and treatments into quality of life of patients. She is involved in collaborations with various researchers from University of Oxford (UK), University of Newcastle, and Cardiology Department at John Hunter hospital.
My current projects are about looking into changes in the blood transfusion patterns in patients with myelodysplastic syndrome who are on hypomethylating agents (azacitidine) as well as looking into their overall survival. It also involves assessing the impact of platelet transfusions on the quality of the life of patients with primary bone marrow disorders. The utilisation of platelets is steadily increasing in Australia. With the increasing use of platelets it is important to assess if our current practice has impact on the quality of life of patients for patient centred approach. It will help us in future to tailor guidelines as well as give direction to future trials. The result of these projects will help to design randomised trial in future in patients with primary bone marrow disorders.
Dr Anoop Enjeti, Dr Milton Hasnat, Dr Mark McEvoy